CAMBRIDGE, Mass. — Convergent Therapeutics Inc. has appointed radiopharmaceutical industry veteran Michael Rossi to its Board of Directors as the company advances its lead prostate cancer therapy into late-stage clinical development.
Rossi brings more than 30 years of experience in radiopharmaceuticals, drug development, and commercial leadership. His appointment comes as Convergent nears completion of a Phase 2 study of CONV01-α, a prostate-specific membrane antigen (PSMA)-targeted Actinium-225 radioantibody being evaluated in patients with metastatic castration-resistant prostate cancer.
Rossi currently serves as CEO of SHINE SPECT USA, LLC, and previously led Y-mAbs Therapeutics as President and CEO until its acquisition by SERB Pharmaceuticals in 2025. His background also includes leadership roles at Mirion Technologies, Advanced Accelerator Applications, a Novartis company, and Jubilant Pharma, where he served as President of Jubilant Radiopharma.
“Michael’s appointment comes at an important moment as the field begins a significant pivot toward new alpha-based radiotherapies,” said Philip Kantoff, M.D., Chief Executive Officer and Co-Founder of Convergent Therapeutics. “He brings a rare combination of radiopharmaceutical expertise, operational leadership, and commercial experience across the full value chain. As we further advance our CONV01-α radioantibody program in mCRPC, Michael’s perspective on building and scaling differentiated radiopharma companies will be invaluable.”
“Convergent has a world-class leadership team and has built one of the most compelling platforms in prostate cancer with an approach that harnesses antibodies as precision delivery vehicles for Ac-225 and could fundamentally overcome the limitations of other PSMA-targeted therapies,” said Mr. Rossi. “I’m honored to join the board and work alongside this exceptional team to bring that promise to patients.”
In addition to his current role, Rossi has held leadership positions at GE Healthcare, Tyco Healthcare/Mallinckrodt, and Syncor International. He also serves on the board of directors of Nucleus RadioPharma and holds a Bachelor of Science in Pharmacy from the University of the Sciences in Philadelphia, along with an Authorized Nuclear Pharmacist Certification from Butler University.
